[
  {
    "ts": null,
    "headline": "Is Boston Scientific (BSX) Pricing In Too Much Optimism After Mixed Share Performance?",
    "summary": "If you are wondering whether Boston Scientific's current share price still lines up with its long term potential, you are not alone. The key question is what the stock is really worth today. The shares last closed at US$92.51, with returns of 5.0% over the past week, a 3.8% decline over the past month, a 2.3% decline year to date, and a 9.3% decline over the past year. The 3 year and 5 year returns sit at 101.5% and 161.0% respectively. Recent news around Boston Scientific has focused on its...",
    "url": "https://finnhub.io/api/news?id=f2d8b9b468dcd95bf9e19d9fa625b0c89e70a489db09543ce8244f84845205f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769267522,
      "headline": "Is Boston Scientific (BSX) Pricing In Too Much Optimism After Mixed Share Performance?",
      "id": 138245887,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "If you are wondering whether Boston Scientific's current share price still lines up with its long term potential, you are not alone. The key question is what the stock is really worth today. The shares last closed at US$92.51, with returns of 5.0% over the past week, a 3.8% decline over the past month, a 2.3% decline year to date, and a 9.3% decline over the past year. The 3 year and 5 year returns sit at 101.5% and 161.0% respectively. Recent news around Boston Scientific has focused on its...",
      "url": "https://finnhub.io/api/news?id=f2d8b9b468dcd95bf9e19d9fa625b0c89e70a489db09543ce8244f84845205f6"
    }
  },
  {
    "ts": null,
    "headline": "Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock.",
    "summary": "Boston Scientific  is all about acquisitions.  In our bullish thesis last October, we wrote how the $136 billion maker of surgical devices, centering on cardiac procedures, uses acquisitions as part of its growth strategy.  Well, its latest acquisition—the aforementioned agreement to acquire  Penumbra  for $14.5 billion, which will likely close this year—has pushed shares down.",
    "url": "https://finnhub.io/api/news?id=e1750a836aa8cc7456698a0f50953b5c4df484d3753e58346a8e5973619af86d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769235480,
      "headline": "Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock.",
      "id": 138235949,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific  is all about acquisitions.  In our bullish thesis last October, we wrote how the $136 billion maker of surgical devices, centering on cardiac procedures, uses acquisitions as part of its growth strategy.  Well, its latest acquisition—the aforementioned agreement to acquire  Penumbra  for $14.5 billion, which will likely close this year—has pushed shares down.",
      "url": "https://finnhub.io/api/news?id=e1750a836aa8cc7456698a0f50953b5c4df484d3753e58346a8e5973619af86d"
    }
  }
]